- Home
- LYEL vs ANGO Comparison
LYEL vs ANGO Comparison
Compare LYEL & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | ANGO |
|---|---|---|
| Founded | 2018 | 1988 |
| Country | United States | United States |
| Employees | N/A | 675 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.9M | 462.0M |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | LYEL | ANGO |
|---|---|---|
| Price | $23.00 | $11.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $25.00 | $19.33 |
| AVG Volume (30 Days) | 89.8K | ★ 383.3K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.92 |
| EPS | N/A | ★ N/A |
| Revenue | $61,000.00 | ★ $291,010,000.00 |
| Revenue This Year | N/A | $9.11 |
| Revenue Next Year | N/A | $4.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $0.39 | $8.27 |
| 52 Week High | $45.00 | $13.99 |
Technical Indicators
Market Signals| Indicator | LYEL | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 54.73 |
| Support Level | $21.72 | $10.37 |
| Resistance Level | $27.30 | $11.92 |
| Average True Range (ATR) | 2.60 | 0.43 |
| MACD | -0.09 | 0.12 |
| Stochastic Oscillator | 36.63 | 71.11 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.